Owen O'Connor
MD, PhD
Professor of Medicine and Director, Center for Lymphoid Malignancies
👥Biography 个人简介
Owen O'Connor led the development and clinical investigation of pralatrexate, the first drug approved specifically for relapsed/refractory PTCL based on the PROPEL trial. His research has been foundational in establishing regulatory pathways for novel agents in T-cell lymphomas and demonstrating proof-of-concept for antifolate therapy in this disease. He is an international advocate for T-cell lymphoma clinical trial development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Owen O'Connor 的研究动态
Follow Owen O'Connor's research updates
留下邮箱，当我们发布与 Owen O'Connor（Columbia University Irving Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment